← Eichor
Study identifier: NCT05851105 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia

Condition: α-thalassemia  ·  Sponsor: Shenzhen Hemogen

PhaseEARLY_Phase 1
Planned participants3
Who can joinAll sexes, 12 Years to 35 Years
Healthy volunteersNo

About this study

This is an open label study to evaluate the safety and efficacy of α-globin Restored Autologous Hematopoietic Stem Cells in α-Thalassemia Major Patients

This description comes directly from the study's public registry record.

Talk to the study team

Haigang Sun  ·  13823168465  ·  sunhaigang@genomics.cn

Always discuss trial participation with your own doctor first.

Locations (1)

PLA Joint Logistic Support Force No. 923 HospitalNanning, Guangxi, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05851105